je.st
news
Tag: of
Keep eye out for light at end of pork tunnel
2016-10-12 15:16:00| National Hog Farmer
Though the current market situation casts a dark shadow over the swine industry, Minnesota Pork Board President, Kevin Estrem, is optimistic that there is a bright light at the end of the tunnel. read more
Google Taps Pixar, Onion Staff to Give AI Assistant a Sense of Humor
2016-10-11 19:02:23| PC Magazine Software Product Guide
The tech titan has reportedly hired joke writers to infuse the AI with a funny bone.
$11 million donation fuels plans for new business school facility at University of Cincinnati
2016-10-10 21:55:00| American School & University
Gift will help pay for $120 million facility scheduled to open in 2019. read more
Tags: of
business
school
university
Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Mercks KEYTRUDA (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients
2016-10-09 08:16:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-024, Published in The New England Journal of Medicine, Showed KEYTRUDA as Monotherapy Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with High Levels of PD-L1 Expression KEYNOTE-021, Cohort G, Published in The Lancet Oncology, Showed KEYTRUDA in Combination with Chemotherapy Demonstrated Superior Efficacy Compared to Chemotherapy Alone as First-Line Treatment; Trial Enrolled Patients Regardless of PD-L1 Expression KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two major studies of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology: Language: English Contact: Media:Pamela Eisele, 267-305-3558Kim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
range
major
potential
Navigant forecasts strong growth in stop-start vehicle sales; 48V systems to account for 15% of those by 2025
2016-10-08 14:55:17| Green Car Congress
Sites : [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] [303] [304] [305] [306] [307] [308] [309] [310] next »